Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma

Table 1

Clinical characteristics of the patients.

Variable	NBNC	B/C	value
	Age (yr)^†	71.0 ± 8.1		68.2 ± 8.9	0.12
Male	73% (22/30)	68% (96/141)	0.57
Accompanied by LC	90% (27/30)	84% (118/141)	0.38
Child-Pugh (A/B, C)	17/10	74/44	0.81
Platelet (×10^4/mL)^†	13.0 ± 6.4	11.4 ± 5.2	0.16
ALT (IU/L)^‡	25 (8–1858)	35 (11–320)	0.45
AFP (ng/mL)^‡	6.6 (2.2–41719)	14.1 (1.6–150300)	0.76
DCP (mAU/mL)^‡	48 (9–40753)	22 (7–99760)	0.35
Tumor size (mm)^†	31.4 ± 19.4	21.8 ± 16.0	<0.01
Tumor number ()^†	1.8 ± 1.5	1.7 ± 1.3	0.42
Vascular invasion (yes/no)	20% (6/30)	4% (6/141)	<0.01
TNM stage (I, II/III, and IV)	18/12	108/33	0.06
Curative therapy	63% (19/30)	68% (96/141)	0.18
No surveillance	47% (14/30)	12% (17/141)	<0.01
Semiannual surveillance	40% (12/30)	57% (81/141)	0.08

Mean ± SD, ^‡median (range), and curative therapy which includes operative resection and radiofrequency ablation.